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Background/aim: Vitamin B12 plays an important role in the development of mental, motor, cognitive, and social functions via its role
in DNA synthesis and nerve myelination. Its deficiency in infants might cause neuromotor retardation as well as megaloblastic anemia.
The objective of this study was to investigate the effects of infantile vitamin B12 deficiency on evoked brain potentials and determine
whether improvement could be obtained with vitamin B12 replacement at appropriate dosages.
Materials and methods: Thirty patients with vitamin B12 deficiency and 30 age-matched healthy controls were included in the study.
Hematological parameters, visual evoked potentials, and brainstem auditory evoked potentials tests were performed prior to treatment,
1 week after treatment, and 3 months after treatment.
Results: Visual evoked potentials (VEPs) and brainstem auditory evoked potentials (BAEPs) were found to be prolonged in 16 (53.3%)
and 15 (50%) patients, respectively. Statistically significant improvements in VEP and BAEP examinations were determined 3 months
after treatment. Three months after treatment, VEP and BAEP examinations returned to normal in 81.3% and 53.3% of subjects with
prolonged VEPs and BAEPs, respectively.
Conclusion: These results demonstrate that vitamin B12 deficiency in infants causes significant impairment in the auditory and visual
functioning tests of the brain, such as VEP and BAEP.
Key words: Vitamin B12 deficiency, infant, visual evoked potentials, auditory evoked potentials

1. Introduction
Vitamin B12 is commonly found in foods of animal origin
and is not synthesized in the human body. Vitamin B12, along
with folic acid, participates in DNA synthesis and plays a
role in nerve myelination, cell division, and proliferation. In
babies exclusively fed with breast milk, the most common
cause of vitamin B12 deficiency is insufficient intake from
vegetarian or vegan mothers who do not consume foods
of animal origin (1). The severity of clinical symptoms is
directly related to the severity of vitamin B12 deficiency
in the mother (2). The most common findings of vitamin
B12 deficiency are hematological and neurological signs.
Several studies have reported that these neurological signs
might be caused by demyelination, dysmyelination, and
axonopathy (3). Abnormalities of visual evoked potentials
(VEPs) and brainstem auditory evoked potentials (BAEPs)
develop secondarily to demyelination and axonopathy
caused by vitamin B12 deficiency. The persistence of VEP
and BAEP abnormality in the deficiency of vitamin B12
* Correspondence: demirnihat27@hotmail.com
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might be associated with delayed diagnosis of vitamin
B12 deficiency and advanced neurological picture (3–6).
The other findings are as follows: growth-developmental
retardation, gastrointestinal motility disorders (diarrhea),
hyperpigmentation, stomatitis, glossitis, irritability,
weakness, lethargy, hypotonia, ataxia, hyporeflexia, tremor,
convulsion, movement disorders, abnormal mental states,
retardation in acquired motor skills, and coma (2,4,7–9).
We could not find any controlled study in the literature
about the effects of vitamin B12 deficiency on the evoked
brain potentials in infants. Thus, in this study we aimed to
determine the effects of vitamin B12 deficiency on VEP and
BAEP in infants, and to investigate the results of treatment.
2. Materials and methods
2.1. Patient selection
A total of 30 infants aged 6–24 months with retardation
of mental, motor, cognitive, and social functions and
diagnosed with moderate or severe vitamin B12 deficiency
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were included in the study. Because vitamin B12 deficiency
causes retardation of mental, motor, cognitive, and social
development, the serum vitamin B12 levels of these patients
were checked. A total of 30 healthy age-matched infants
were enrolled in the study as the control group. Written
informed consent was obtained from the families of each
subject. Detailed nutrition and developmental history
was obtained for each child, and the level of physical
development was determined with a physical examination.
Weight, height, and head circumferences were measured
in each infant, and physical development by age was
determined using the percentile curves developed by Neyzi
et al. (10). This study was performed in a region where
the population is large, birth rate is high, and nutritional
vitamin B12 deficiency is common due to sociocultural and
nutritional habits (11). All patients in the study group were
normal by percentile curves for age.
Procedures were carried out according to the ethical
standards for human experimentation established by
the Declaration of Helsinki of 1975, revised in 1983. The
study was approved by the ethics committee of Harran
University. Consent forms were signed by the parents
before the study began.
2.2. Exclusion criteria
The exclusion criteria were as follows: patients with
congenital abnormality, history of asphyxia during or
after delivery, history of convulsion, degenerative and
demyelinating diseases, or any chronic diseases were
excluded from the study. Patients with malnutrition were
also excluded due to the possible deficiency of other
vitamins and minerals that would affect the VEP and
BAEP examinations. Patients with iron deficiency anemia
or folic acid deficiency alone or together with vitamin B12
deficiency were also excluded from the study.
2.3. Blood samples
Complete blood count was examined using an automatic
blood count device (Celldyn 3500), and levels of
vitamin B12, folic acid, and ferritin were determined by
electrochemiluminescence (Elecsys 2010) in 2 h. Blood
samples obtained for the determination of serum iron and
total iron binding capacity were centrifuged and stored
at –80 °C to be examined by biochemical autoanalyzer
(Abbot Aeroset, UK) using a photometric method within
1 month. A serum vitamin B12 level lower than 200 pg/dL
was considered as a deficiency, and a level lower than 100
pg/dL was considered as a severe deficiency.
2.4. VEP examinations
VEP tests were administered to all subjects using a Dantec
Keypoint standard EMG device (Dantec, Denmark).
During VEP response assessment, subjects were placed
90 cm from the TV monitor (Philips, the Netherlands) in
order to see a visual stimulus. These tests were performed

using checker-board pattern reversal. Stimuli were
introduced as a checker-board pattern of white and black
squares changing every 20 ms on the monitor. In VEP
tests, an electrode was placed on the scalp in the midline
over the occipital region, 5 cm above the inion (Oz). A
reference electrode was placed over the frontal region
and the ground electrode was placed on the forearm.
Frequency limits were 0.5–100 Hz and analysis time was
500 ms. A repeated trial to verify reproducibility of the test
was performed. Section was chosen as 5 µV (12).
2.5. BAEP examinations
The BAEP test studies the brainstem-evoked potentials
that are produced in response to an auditory click stimulus
and are measured from the scalp during the first 8–10
ms. Measurements are made using superficial electrodes
placed at the center of the vertex (Cz) and mastoid process
(or earlobe). A minimum of 1000 stimuli are produced
and the potentials (the signal is magnified 500,000–
1,000,000 times) are recorded repetitively to demonstrate
reproducibility. Seven potentials are determined in the
first 10 ms and are represented by Roman numerals. Waves
I to V are observed in all healthy adults, whereas waves
VI and VII are seen in only 43%–84% of adults. Waves IV
and V are the most marked components of BAEPs. The
upper limit was accepted as 167 ms in the P100 latency
wave of VEP, 2.73 ms in I–III interpeak latency waves of
BAEP, 5.30 ms in I–V latency waves, and 2.35 ms in III–V
interpeak latency waves in the age range of 1 month to 2
years. Prolongation of one of the interpeak latency periods
determined in these tests was considered abnormal (13).
Intramuscular cyanocobalamin, a vitamin B12 derivative,
was administered to the subjects with vitamin B12
deficiency at a dosage of 10 µg/day in the first 3 days,
100 µg on day 4, and 500 µg on day 5 of the treatment.
Maintenance treatment was administered as 5 doses of
1 mg/day of vitamin B12 every other day. Hematological
and biochemical tests as well as VEP and BAEP tests were
repeated on day 8 (week 1 of treatment) and month 3 of
treatment.
2.6. Statistical analysis
Intergroup rate comparisons were performed with
Pearson chi-square test. Pre- and posttreatment median
(interquartile range) values were compared using Friedman
and Wilcoxon tests. The rates of abnormality in pre- and
posttreatment VEPs and BAEPs were compared with
Pearson chi- square and McNemar tests. All calculations
were performed on a computer using SPSS 11.5.
3. Results
The 30 patients in the study group consisted of 17 males
and 13 females with a mean age of 13.3 ± 4.9 months.
The control group consisted of 18 males and 12 females
with a mean age of 13.6 ± 4.2 months. There was no
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statistically significant difference between groups in
terms of sex and age (P > 0.05). Twenty-five (83.3%) of
patients with vitamin B12 deficiency were exclusively
breast-fed, whereas 3 (10%) subjects were breast-fed and
also received additional nutrients. One subject (3.3%) was
fed with formula milk and another (3.3%) with cow milk.
Of the 30 patients in the study group, 73.3% had vitamin
B12 levels lower than 100 pg/dL, which was considered as
severe B12 deficiency, whereas 26.7% had a vitamin B12
level below 200 pg/dL, which was considered as mild B12
deficiency. The families of 90% of the patients were of low
socioeconomic status. Consumption of meat and dairy
products was quite low in these families, although there
was no vegetarian mother. Maternal serum vitamin B12
levels were below 200 pg/dL in 77% of the 30 patients and
were also below 100 pg/dL, defined as severe deficiency, in
28% of patients. The most common symptoms were motor
retardation, hypotonia, skin hyperpigmentation, no eye
contact, social retardation, papilla atrophy of the tongue,
and hematologic manifestations (pallor, petechiae, etc.).
The sociodemographic and clinical characteristics of the
patients are presented in Table 1. Hematological findings
in all patients improved significantly after the first and
third month of treatment. Neuromotor retardation and
hypotonia were observed in 28 patients; 24 patients had a
good response to vitamin B12 treatment, whereas 4 patients
did not respond to the treatment.
The laboratory examinations of each group are
shown in Table 2. Values of hemoglobin and vitamin B12
Table 1. Sociodemographic and clinical characteristics of the
patients.
Number of patients
(n: 30) (%)
Boys

17 (43)

Girls

13 (43)

Patient’s vitamin B12 (<100 pg/dL)

22 (73)

Patient’s vitamin B12 (100–200 pg/dL)

8 (27)

Exclusively breast-fed

25 (83)

Living in rural areas

27 (90)

Motor retardation

28 (93)

Hypotonia

28 (93)

Paleness

27 (90)

Skin hyperpigmentation

23 (76)

No eye contact, social retardation

19 (63)

Papilla atrophy of tongue

19 (63)

Irritability

7 (23)
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were statistically significantly lower in the patient group
compared to the controls. Pretreatment mean ferritin
and mean corpuscular volume (MCV) were statistically
significantly higher in the patient group compared to the
controls. VEPs and BAEPs were abnormal in 16 (53.3%) and
15 (50%) of the infants in the patient group, respectively,
and normal in all of the control subjects. These differences
were statistically significant (P < 0.001). When the median
VEP values from the right and left eyes of the patients
were compared with those of the controls, statistically
significant prolongation was found in the patient group.
Additionally, when we compared these groups in terms of
BAEP I–III, III–V, and I–V interpeak latencies, there was
also a statistically significant prolongation in the patient
group (Table 2). Three months after treatment, statistically
significant improvements were observed in both VEP and
BAEP interpeak latencies (Table 3). The comparison of
median VEP and BAEP values of infants with vitamin B12
deficiency before and after treatment are shown in Table 4.
When we compared the median VEP and BAEP interpeak
latencies between pretreatment and 7 days after treatment,
no statistically significant improvement was found, except
for BAEP III–V interpeak latency. Additionally, when
we compared the median VEP and BAEP interpeak
latencies between 7 days and 3 months after treatment, no
statistically significant improvement was found, except for
the left-eye VEP values (Table 3).
The rates of infants with vitamin B12 deficiency who
showed improved VEP and BAEP abnormality with
treatment are shown. Before the treatment, 16 and 15
patients had abnormal (prolonged) VEP and BAEP
examinations, respectively. After 7 days of treatment,
improvements or normalization of VEP and BAEP
examinations were observed in 3 and 5 patients, respectively.
These improvement rates were not statistically significant.
Three months after treatment, from a total of 16 infants
with abnormal VEP and 15 infants with abnormal BAEP
examinations, improvements or normalization of VEP
and BAEP examinations were found in 13 and 8 patients,
respectively. These improvement rates were statistically
significant compared to pretreatment (Table 4). Subjects
with persistent VEP and BAEP abnormality at 3 months
were those with severe vitamin B12 deficiency (<100 pg/
dL) at baseline.
4. Discussion
To the best of our knowledge, this study is the largest
published study on a prospective cohort of patients with
impaired visual and auditory potentials (VEPs, BAEPs) who
might develop secondary to early vitamin B12 deficiency.
Weakness and failure to thrive were the most commonly
observed manifestations of vitamin B12 deficiency in
the present study. Neurological, gastrointestinal, and
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Table 2. Comparison of mean VEP, BAEP, and hematological and anthropometric parameters in
patient and control groups.
Patient group
mean ± SD

Control group
mean ± SD

P

Hb (g/dL)

8.82 ± 2.60

11.22 ± 0.99

<0.001

MCV (fL)

87.87 ± 11,29

75.27 ± 2.51

<0.001

Ferritin (ng/dL)

56.46 ± 20.8

38 ± 9.4

<0.003

Vitamin B12 (pg/dL)

82.00 ± 47.80

486.66 ± 177.07

<0.001

BAEP I–III interpeak latency (ms)

2.4 ± 0.6

2.1 ± 0.2

<0.001

BAEP I–V interpeak latency (ms)

4.8 ± 1.5

4.2 ± 0.2

<0.001

BAEP III–V interpeak latency (ms)

2.5 ± 0.9

2.2 ± 0.2

<0.001

Right VEP (ms)

170 ± 65

126 ± 12.2

<0.001

Left VEP (ms)

165 ± 50

125 ± 11.2

<0.001

BAEP: Brainstem auditory-evoked potential, VEP: visual evoked potential.
Table 3. Median VEP and BAEP values of children with vitamin B12 deficiency before and after treatment.

Pretreatment median
(interquartile range)
(ms)

7 days after
treatment median
(interquartile range)
(ms)

BAEP I–III interpeak latency

2.4 ± 0.6

2.3 ± 0.7

BAEP I–V interpeak latency

4.8 ± 1.5

4.6 ± 0.6

BAEP III–V interpeak latency

2.5 ± 0.9

Right VEP
Left VEP

3 months after
treatment median
(interquartile range)
(ms)

P
Pretreatment vs.
7 days after
treatment

7 days after
treatment vs.
3 months after
treatment

Pretreatment vs.
3 months after
treatment

>0.05

>0.05

<0.001

4.6 ± 0.4

>0.05

>0.05

<0.01

2.4 ± 0.4

2.4 ± 0.3

<0.05

>0.05

<0.01

170 ± 65

145 ± 37

134 ± 26

>0.05

>0.05

<0.01

165 ± 50

142 ± 34

135 ± 22

>0.05

<0.05

<0.01

2.2 ± 0.3

BAEP: Brainstem auditory evoked potential, VEP: visual evoked potential.

Table 4. VEP and BAEP abnormality with vitamin B12 deficiency before and after treatment.
Pretreatment

7 days after treatment

3 months after treatment

Prolonged
n (%)

Prolonged
n (%)

Improved
n (%)

Prolonged
n (%)

Improved
n (%)

VEP¥

16 (100)a

13 (81.3)

3 (18.7)c**

3 (18.7)

13 (81.3) b**

BAEP€

15 (100)a

10 (66.7%)

5 (33.3)c

7 (46.7)

8 (53.3) b*

: On admission, of a total of 30 patients, 16 had prolonged and 14 had normal VEP examinations.
: On admission, of a total of 30 patients, 15 had prolonged and 15 had normal BAEP examinations.
BAEP: Brainstem auditory evoked potential, VEP: visual evoked potential.
a: No significant differences were determined in terms of VEP and BAEP abnormalities between the pretreatment and day 7 values.
b: Comparison of pretreatment and month 3 values, * P < 0.01, ** P < 0.001.
c: Comparison of 7 days and 3 months after treatment, ** P < 0.001.
¥
€
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hematological symptoms were observed in 18%, 27%, and
51% of the patients, respectively (14). These neurological
signs may be caused by demyelination, dysmyelination,
and axonopathy (3). Abnormalities of VEP and BAEP
developed secondarily to demyelination and axonopathy
caused by vitamin B12 deficiency. The persistence of VEP
and BAEP abnormality in the deficiency of vitamin B12
might be associated with delayed diagnosis of vitamin
B12 deficiency and advanced neurological view (4,6). In a
study carried out by Biancheri et al. (6), out of 14 cases
with congenital cobalamin metabolism disorder, the BAEP
results of 9 and the VEP results of 8 cases were determined
to be abnormal. It was observed that of the 6 patients
with abnormal BAEP test results, 3 recovered completely
6 months after treatment and another 3 recovered
completely 10 months after treatment. It was thought that
the neurophysiological anomalies in these cases had arisen
due to demyelination. In this study, 15 of 30 patients were
determined as having abnormal BAEP test results. After
treatment with vitamin B12, 5 and 3 of these patients
recovered in 1 week and 3 months, respectively.
In a study carried out by Misra et al. (15), a VEP test
was carried out in 13 patients with neurological findings
due to vitamin B12 deficiency. The VEP latencies of 7
patients were determined to be long, and these changes
were attributed to the focal demyelination of white matter
in the optical nerve and spinal cord due to vitamin B12
deficiency. In this study, 16 of 30 patients were determined
as having abnormal VEPs. After treatment with vitamin
B12, 3 patients were observed to have recovered within 1
week and 10 patients after 3 months.
Studies have demonstrated that the rate of VEP
abnormality ranges between 25%and 100% in patients
with vitamin B12 deficiency (3,4). Although BAEP
abnormality has been reported in 0%–100% of subjects in
previous studies performed on small patient populations,
it has been emphasized that VEP abnormality is more
common compared to BAEP abnormality (3,16,17). The
minimal alterations in BAEP have suggested that BAEP is
affected minimally in the deficiency of vitamin B12 (3).
The main limitation of our study is the limited number
of infants. However, in the present study, the number
of subjects was greater compared to other studies in
the literature, and VEP and BAEP were abnormal in
53.3% and 50% of subjects, respectively. The evident
improvement in VEP compared to BAEP at 3 months
has been considered as an indirect indicator that vitamin
B12 deficiency affects VEP more significantly. VEP and
BAEP values improved in 81.3% and 53.3% of patients
at 3 months compared to pretreatment values, which
suggested that the abnormalities in both VEP and BAEP
developed secondarily to demyelination and axonopathy
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caused by vitamin B12 deficiency. Similar to other studies
in the literature, these results suggest that vitamin B12
deficiency affects VEP more significantly than BAEP
(3,4,6). However, the improvement of BAEP is slower than
the improvement of VEP.
Previous studies have demonstrated that there is a
positive correlation between the degree of vitamin B12
deficiency and abnormality of evoked brain potentials
(4,6,18,19). Similarly, in this study, VEP and BAEP tests
proved abnormal in 3 and 7 subjects who had serum
vitamin B12 levels of <100 pg/mL, respectively. Two patients
were presented by Renault et al. (19), and it was observed
that one patient who showed apathy and lack of interest
in the environment recovered at the end of the first week
following treatment, whereas the neurological findings
of the other patient healed after 2 months. The difference
in the recovery of these neurological findings has been
attributed to late diagnosis and late treatment (19). The
persistence of VEP and BAEP abnormality in our patients
at 3 months might be associated with delayed diagnosis of
vitamin B12 deficiency and advanced neurological picture.
We found maternal vitamin B12 deficiency in 77% of 30
patients with vitamin B12 deficiency, and the deficiency was
severe (serum B12 levels <100 pg/dL) in 28% of mothers. The
facts that vitamin B12 deficiency emerged most commonly
between the ages of 6 and 18 months, that maternal serum
vitamin B12 levels were reduced in most cases, and that
maternal nutrition was poor in vitamin B12-containing
foods suggest that infantile deficiency of vitamin B12 was
secondary to maternal deficiency. Therefore, our results
support those of previous studies (11, 20–24).
Infants who were born to mothers with vitamin B12
deficiency have inadequate myelination during gestation
and particularly in the last trimester, when myelination
is normally at its most rapid. The neurological picture
becomes even more severe in the absence of postpartum
vitamin B12 replacement in the first 6 months of infancy,
which is the rapid myelination period. As a result, brain
atrophy and permanent neurological deficits develop
(8,25). The neurological symptoms that arise due to the
late diagnosis and treatment of vitamin B12 deficiency
either do not recover completely or are healed over a long
period of time (26).
In conclusion, this study has demonstrated that
symptoms of mental, motor, cognitive, and social
retardation with impaired visual and auditory potentials
(VEP, BAEP) might develop secondary to early vitamin B12
deficiency in exclusively breast-fed infants whose mothers
consume inadequate animal products. Early diagnosis and
treatment of vitamin B12 deficiency might prevent severe
mental and motor retardations, which might be difficult to
treat or irreversible.
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